ArticleExperimental animals2026
Honghe Fujie lotion ameliorates pregnancy-associated vulvovaginal candidiasis in mice by inhibiting the activation of NLRP3 inflammasome.
Article in Experimental animals, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal candidiasis, a common infection of the female reproductive tract, poses heightened risks when occurring during pregnancy. Although Honghe Fujie lotion (HFL), a traditional Chinese medicine, is clinically used for mycotic vaginitis, its therapeutic efficacy and mechanisms in pregnancy-associated vulvovaginal candidiasis (pVVC) remain unclear. In this study, HPLC-MS was used to analyze and identify the compounds in HFL. This study investigated HFL's effects through in vitro and in vivo approaches. A murine model of vaginal Candida albicans (C. albicans) infection was established to evaluate the therapeutic effect of HFL on pVVC. Vaginal fungal load was quantified by analyzing vaginal lavage fluid, while the impact of HFL on adverse pregnancy outcomes was assessed through placental developmental analysis. Furthermore, the effects of HFL on pVVC-induced vaginitis and NLRP3 inflammasome activation were examined using immunofluorescence, enzyme-linked immunosorbent assay, and western blot. The results included: (1) High performance liquid chromatography coupled with mass spectrometry (HPLC-MS) analysis identified 545 chemical constituents in HFL. (2) HFL significantly inhibited C. albicans growth and biofilm metabolic activity in vitro; (3) in a murine pVVC model, HFL reduced vaginal fungal load and mitigated adverse pregnancy outcomes, while also restoring trophoblast cell distribution in placental tissues; (4) mechanistically, HFL suppressed NLRP3 inflammasome activation, leading to Caspase-1 activity downregulation and subsequent impairment of pro-inflammatory cytokine secretion. These findings demonstrate that HFL alleviates pVVC by targeting the NLRP3 signaling pathway, providing a preclinical foundation for its therapeutic application in pregnancy-associated VVC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.